GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hualan Biological Engineering Inc (SZSE:002007) » Definitions » Tangible Book per Share

Hualan Biological Engineering (SZSE:002007) Tangible Book per Share : ¥6.17 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Hualan Biological Engineering Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Hualan Biological Engineering's tangible book value per share for the quarter that ended in Mar. 2024 was ¥6.17.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Hualan Biological Engineering Tangible Book per Share Historical Data

The historical data trend for Hualan Biological Engineering's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hualan Biological Engineering Tangible Book per Share Chart

Hualan Biological Engineering Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tangible Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.47 4.01 4.45 5.52 6.02

Hualan Biological Engineering Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.71 5.50 5.79 6.02 6.17

Competitive Comparison of Hualan Biological Engineering's Tangible Book per Share

For the Biotechnology subindustry, Hualan Biological Engineering's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hualan Biological Engineering's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hualan Biological Engineering's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Hualan Biological Engineering's Price-to-Tangible-Book falls into.



Hualan Biological Engineering Tangible Book per Share Calculation

Hualan Biological Engineering's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(11359.431-0-347.083)/1828.78
=6.02

Hualan Biological Engineering's Tangible Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(11631.478-0-349.847)/1828.78
=6.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Hualan Biological Engineering  (SZSE:002007) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Hualan Biological Engineering Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Hualan Biological Engineering's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Hualan Biological Engineering (SZSE:002007) Business Description

Traded in Other Exchanges
N/A
Address
No. A1 Hualan Avenue, Henan Province, Xinxiang, CHN, 453003
Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.
Executives
An Kang Directors, executives
Pan Ruo Wen Executives
An Wen Qi Executives
Wang Qi Ping Directors, executives
Fan Bei Directors, executives
Ma Xiao Wei Executives
Xie Jun Min Directors, executives
Zhang Bao Xian Executives
Lv Cheng Yu Securities Affairs Representative
Zhang Jin Gang Independent director
Wang Li Ting Independent director
Ma Li Supervisors
Sun Zhen Guo Supervisors
Chen Lei Shan Supervisors
Yang Bao Ping Supervisors

Hualan Biological Engineering (SZSE:002007) Headlines

No Headlines